Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Blocking the Thrombin Receptor Promotes Repair of Demyelinated Lesions in the Adult Brain.

Yoon H, Choi CI, Triplet EM, Langley MR, Kleppe LS, Kim HN, Simon WL, Scarisbrick IA.

J Neurosci. 2020 Jan 7. pii: 2029-19. doi: 10.1523/JNEUROSCI.2029-19.2019. [Epub ahead of print]

PMID:
31911460
2.

High fat diet consumption results in mitochondrial dysfunction, oxidative stress, and oligodendrocyte loss in the central nervous system.

Langley MR, Yoon H, Kim HN, Choi CI, Simon W, Kleppe L, Lanza IR, LeBrasseur NK, Matveyenko A, Scarisbrick IA.

Biochim Biophys Acta Mol Basis Dis. 2020 Mar 1;1866(3):165630. doi: 10.1016/j.bbadis.2019.165630. Epub 2019 Dec 6.

PMID:
31816440
3.

Protein kinase D up-regulates transcription of VEGF receptor-2 in endothelial cells by suppressing nuclear localization of the transcription factor AP2β.

Wang Y, Hoeppner LH, Angom RS, Wang E, Dutta S, Doeppler HR, Wang F, Shen T, Scarisbrick IA, Guha S, Storz P, Bhattacharya R, Mukhopadhyay D.

J Biol Chem. 2019 Oct 25;294(43):15759-15767. doi: 10.1074/jbc.RA119.010152. Epub 2019 Sep 6.

PMID:
31492751
4.

Microenvironment proteinases, proteinase-activated receptor regulation, cancer and inflammation.

Eftekhari R, de Lima SG, Liu Y, Mihara K, Saifeddine M, Noorbakhsh F, Scarisbrick IA, Hollenberg MD.

Biol Chem. 2018 Sep 25;399(9):1023-1039. doi: 10.1515/hsz-2018-0001.

PMID:
29924723
5.

The Thrombin Receptor Restricts Subventricular Zone Neural Stem Cell Expansion and Differentiation.

Choi CI, Yoon H, Drucker KL, Langley MR, Kleppe L, Scarisbrick IA.

Sci Rep. 2018 Jun 19;8(1):9360. doi: 10.1038/s41598-018-27613-9.

6.

Kallikrein-related peptidase 6 orchestrates astrocyte form and function through proteinase activated receptor-dependent mechanisms.

Yoon H, Radulovic M, Scarisbrick IA.

Biol Chem. 2018 Sep 25;399(9):1041-1052. doi: 10.1515/hsz-2018-0122.

7.

Protease activated receptor 2 controls myelin development, resiliency and repair.

Yoon H, Radulovic M, Walters G, Paulsen AR, Drucker K, Starski P, Wu J, Fairlie DP, Scarisbrick IA.

Glia. 2017 Dec;65(12):2070-2086. doi: 10.1002/glia.23215. Epub 2017 Sep 18.

8.

Astrocyte heterogeneity across the brain and spinal cord occurs developmentally, in adulthood and in response to demyelination.

Yoon H, Walters G, Paulsen AR, Scarisbrick IA.

PLoS One. 2017 Jul 10;12(7):e0180697. doi: 10.1371/journal.pone.0180697. eCollection 2017.

9.

The progeroid gene BubR1 regulates axon myelination and motor function.

Choi CI, Yoo KH, Hussaini SM, Jeon BT, Welby J, Gan H, Scarisbrick IA, Zhang Z, Baker DJ, van Deursen JM, Rodriguez M, Jang MH.

Aging (Albany NY). 2016 Sep 12;8(11):2667-2688. doi: 10.18632/aging.101032.

10.

Kallikrein-related peptidase 6 exacerbates disease in an autoimmune model of multiple sclerosis.

Yoon H, Scarisbrick IA.

Biol Chem. 2016 Dec 1;397(12):1277-1286. doi: 10.1515/hsz-2016-0239.

11.

Targeting the thrombin receptor modulates inflammation and astrogliosis to improve recovery after spinal cord injury.

Radulovic M, Yoon H, Wu J, Mustafa K, Scarisbrick IA.

Neurobiol Dis. 2016 Sep;93:226-42. doi: 10.1016/j.nbd.2016.04.010. Epub 2016 May 1.

12.

Interplay between exercise and dietary fat modulates myelinogenesis in the central nervous system.

Yoon H, Kleven A, Paulsen A, Kleppe L, Wu J, Ying Z, Gomez-Pinilla F, Scarisbrick IA.

Biochim Biophys Acta. 2016 Apr;1862(4):545-555. doi: 10.1016/j.bbadis.2016.01.019. Epub 2016 Jan 26.

13.

Genetic targeting of protease activated receptor 2 reduces inflammatory astrogliosis and improves recovery of function after spinal cord injury.

Radulovic M, Yoon H, Wu J, Mustafa K, Fehlings MG, Scarisbrick IA.

Neurobiol Dis. 2015 Nov;83:75-89. doi: 10.1016/j.nbd.2015.08.021. Epub 2015 Aug 24.

14.

Prognostic significance of multiple kallikreins in high-grade astrocytoma.

Drucker KL, Gianinni C, Decker PA, Diamandis EP, Scarisbrick IA.

BMC Cancer. 2015 Aug 1;15:565. doi: 10.1186/s12885-015-1566-5.

15.

The thrombin receptor is a critical extracellular switch controlling myelination.

Yoon H, Radulovic M, Drucker KL, Wu J, Scarisbrick IA.

Glia. 2015 May;63(5):846-59. doi: 10.1002/glia.22788. Epub 2015 Jan 27.

16.

Differential expression of multiple kallikreins in a viral model of multiple sclerosis points to unique roles in the innate and adaptive immune response.

Panos M, Christophi GP, Rodriguez M, Scarisbrick IA.

Biol Chem. 2014 Sep;395(9):1063-73. doi: 10.1515/hsz-2014-0141.

17.

Kallikrein cascades in traumatic spinal cord injury: in vitro evidence for roles in axonopathy and neuron degeneration.

Radulovic M, Yoon H, Larson N, Wu J, Linbo R, Burda JE, Diamandis EP, Blaber SI, Blaber M, Fehlings MG, Scarisbrick IA.

J Neuropathol Exp Neurol. 2013 Nov;72(11):1072-89. doi: 10.1097/NEN.0000000000000007.

18.

Critical role for PAR1 in kallikrein 6-mediated oligodendrogliopathy.

Burda JE, Radulovic M, Yoon H, Scarisbrick IA.

Glia. 2013 Sep;61(9):1456-70. doi: 10.1002/glia.22534. Epub 2013 Jul 8.

19.

Kallikrein 6 signals through PAR1 and PAR2 to promote neuron injury and exacerbate glutamate neurotoxicity.

Yoon H, Radulovic M, Wu J, Blaber SI, Blaber M, Fehlings MG, Scarisbrick IA.

J Neurochem. 2013 Oct;127(2):283-98. doi: 10.1111/jnc.12293. Epub 2013 May 27.

20.

Clinical significance and novel mechanism of action of kallikrein 6 in glioblastoma.

Drucker KL, Paulsen AR, Giannini C, Decker PA, Blaber SI, Blaber M, Uhm JH, O'Neill BP, Jenkins RB, Scarisbrick IA.

Neuro Oncol. 2013 Mar;15(3):305-18. doi: 10.1093/neuonc/nos313. Epub 2013 Jan 10.

21.

Activation profiles of human kallikrein-related peptidases by matrix metalloproteinases.

Yoon H, Blaber SI, Li W, Scarisbrick IA, Blaber M.

Biol Chem. 2013 Jan;394(1):137-47. doi: 10.1515/hsz-2012-0249.

22.

Kallikrein 6 is a novel molecular trigger of reactive astrogliosis.

Scarisbrick IA, Radulovic M, Burda JE, Larson N, Blaber SI, Giannini C, Blaber M, Vandell AG.

Biol Chem. 2012 Apr;393(5):355-67. doi: 10.1515/hsz-2011-0241.

23.

Kallikrein 6 regulates early CNS demyelination in a viral model of multiple sclerosis.

Scarisbrick IA, Yoon H, Panos M, Larson N, Blaber SI, Blaber M, Rodriguez M.

Brain Pathol. 2012 Sep;22(5):709-22. doi: 10.1111/j.1750-3639.2012.00577.x. Epub 2012 Mar 21.

24.

Functional role of kallikrein 6 in regulating immune cell survival.

Scarisbrick IA, Epstein B, Cloud BA, Yoon H, Wu J, Renner DN, Blaber SI, Blaber M, Vandell AG, Bryson AL.

PLoS One. 2011 Mar 28;6(3):e18376. doi: 10.1371/journal.pone.0018376.

25.

Functional intersection of the kallikrein-related peptidases (KLKs) and thrombostasis axis.

Blaber M, Yoon H, Juliano MA, Scarisbrick IA, Blaber SI.

Biol Chem. 2010 Apr;391(4):311-20. doi: 10.1515/BC.2010.024. Review.

26.

A completed KLK activome profile: investigation of activation profiles of KLK9, 10, and 15.

Yoon H, Blaber SI, Debela M, Goettig P, Scarisbrick IA, Blaber M.

Biol Chem. 2009 Apr;390(4):373-7. doi: 10.1515/BC.2009.026.

27.

Protease-activated receptor dependent and independent signaling by kallikreins 1 and 6 in CNS neuron and astroglial cell lines.

Vandell AG, Larson N, Laxmikanthan G, Panos M, Blaber SI, Blaber M, Scarisbrick IA.

J Neurochem. 2008 Nov;107(3):855-70. doi: 10.1111/j.1471-4159.2008.05658.x. Epub 2008 Sep 6.

28.

Activation profiles of human kallikrein-related peptidases by proteases of the thrombostasis axis.

Yoon H, Blaber SI, Evans DM, Trim J, Juliano MA, Scarisbrick IA, Blaber M.

Protein Sci. 2008 Nov;17(11):1998-2007. doi: 10.1110/ps.036715.108. Epub 2008 Aug 12.

29.

Kallikreins are associated with secondary progressive multiple sclerosis and promote neurodegeneration.

Scarisbrick IA, Linbo R, Vandell AG, Keegan M, Blaber SI, Blaber M, Sneve D, Lucchinetti CF, Rodriguez M, Diamandis EP.

Biol Chem. 2008 Jun;389(6):739-45. doi: 10.1515/BC.2008.085.

31.

Activation profiles and regulatory cascades of the human kallikrein-related peptidases.

Yoon H, Laxmikanthan G, Lee J, Blaber SI, Rodriguez A, Kogot JM, Scarisbrick IA, Blaber M.

J Biol Chem. 2007 Nov 2;282(44):31852-64. Epub 2007 Sep 6.

32.

The autolytic regulation of human kallikrein-related peptidase 6.

Blaber SI, Yoon H, Scarisbrick IA, Juliano MA, Blaber M.

Biochemistry. 2007 May 1;46(17):5209-17. Epub 2007 Apr 7.

33.

Dynamic role of kallikrein 6 in traumatic spinal cord injury.

Scarisbrick IA, Sabharwal P, Cruz H, Larsen N, Vandell AG, Blaber SI, Ameenuddin S, Papke LM, Fehlings MG, Reeves RK, Blaber M, Windebank AJ, Rodriguez M.

Eur J Neurosci. 2006 Sep;24(5):1457-69.

PMID:
16987227
34.

Potential scope of action of tissue kallikreins in CNS immune-mediated disease.

Scarisbrick IA, Blaber SI, Tingling JT, Rodriguez M, Blaber M, Christophi GP.

J Neuroimmunol. 2006 Sep;178(1-2):167-76. Epub 2006 Jul 7.

PMID:
16824622
35.

Substrate specificity of human kallikrein 6: salt and glycosaminoglycan activation effects.

Angelo PF, Lima AR, Alves FM, Blaber SI, Scarisbrick IA, Blaber M, Juliano L, Juliano MA.

J Biol Chem. 2006 Feb 10;281(6):3116-26. Epub 2005 Dec 1.

36.

1.70 A X-ray structure of human apo kallikrein 1: structural changes upon peptide inhibitor/substrate binding.

Laxmikanthan G, Blaber SI, Bernett MJ, Scarisbrick IA, Juliano MA, Blaber M.

Proteins. 2005 Mar 1;58(4):802-14.

PMID:
15651049
37.

Distinct promoters regulate tissue-specific and differential expression of kallikrein 6 in CNS demyelinating disease.

Christophi GP, Isackson PJ, Blaber S, Blaber M, Rodriguez M, Scarisbrick IA.

J Neurochem. 2004 Dec;91(6):1439-49.

38.

Targeting kallikrein 6 proteolysis attenuates CNS inflammatory disease.

Blaber SI, Ciric B, Christophi GP, Bernett MJ, Blaber M, Rodriguez M, Scarisbrick IA.

FASEB J. 2004 May;18(7):920-2. Epub 2004 Mar 19.

PMID:
15033932
39.

Hit-Hit and hit-Run: viruses in the playing field of multiple sclerosis.

Scarisbrick IA, Rodriguez M.

Curr Neurol Neurosci Rep. 2003 May;3(3):265-71. Review.

PMID:
12760396
40.

Activity of a newly identified serine protease in CNS demyelination.

Scarisbrick IA, Blaber SI, Lucchinetti CF, Genain CP, Blaber M, Rodriguez M.

Brain. 2002 Jun;125(Pt 6):1283-96.

PMID:
12023317
41.

Crystal structure and biochemical characterization of human kallikrein 6 reveals that a trypsin-like kallikrein is expressed in the central nervous system.

Bernett MJ, Blaber SI, Scarisbrick IA, Dhanarajan P, Thompson SM, Blaber M.

J Biol Chem. 2002 Jul 5;277(27):24562-70. Epub 2002 Apr 30.

42.

Enzymatic properties of rat myelencephalon-specific protease.

Blaber SI, Scarisbrick IA, Bernett MJ, Dhanarajan P, Seavy MA, Jin Y, Schwartz MA, Rodriguez M, Blaber M.

Biochemistry. 2002 Jan 29;41(4):1165-73.

PMID:
11802715
43.

MSP, a trypsin-like serine protease, is abundantly expressed in the human nervous system.

Scarisbrick IA, Isackson PJ, Ciric B, Windebank AJ, Rodriguez M.

J Comp Neurol. 2001 Mar 12;431(3):347-61.

PMID:
11170010
44.

Neurotrophin-4/5 promotes proliferation of oligodendrocyte-type-2 astrocytes (O-2A).

Scarisbrick IA, Asakura K, Rodriguez M.

Brain Res Dev Brain Res. 2000 Sep 30;123(1):87-90.

PMID:
11020553
45.

Preferential expression of myelencephalon-specific protease by oligodendrocytes of the adult rat spinal cord white matter.

Scarisbrick IA, Asakura K, Blaber S, Blaber M, Isackson PJ, Bieto T, Rodriguez M, Windebank AJ.

Glia. 2000 May;30(3):219-30.

PMID:
10756072
47.
48.
49.

NCAM immunoreactivity during major developmental events in the rat maxillary nerve-whisker system.

Scarisbrick IA, Jones EG.

Brain Res Dev Brain Res. 1993 Jan 15;71(1):121-35.

PMID:
8431996
50.

Supplemental Content

Loading ...
Support Center